Enabling technologies and Research tools

The Institut Pasteur has successfully transferred a wide range of Research Tools and Enabling Technologies to industry over the last decade. Our extensive portfolio of Research Tools and Enabling Technologies is available for commercialization and new product development opportunities:


  • Genomics/Proteomics
  • Antibodies/Hybridomas
  • Animal models
  • Cell lines
  • Bacterial strains
  • Other materials
  • Software/Computational biology


Selection of Research tools and Enabling Technologies currently available


Invention Disclosure




Didier Mazel

Design and evolution of attC recombination sites with custom recombineering


Patrick Forterre

Exploitation of the pyramid-forming viral protein for modification of cellular and artificial membrane


Miria Richetti

Design of probes to detect initiation of DNA replication of the human mitochondrial genome


Pierre Lafaye

Use of VHHs as transporters: VHHs coupled with GFPs are capable of entering a cell and labeling an intracellular antigen


Y Janin

Halogenated trifluoromethylpyrazoles: very useful building blocks for preparation of 3/5-trifluoromethylpyrazoles or diversely substituted 3/5-carboxypyrazoles


Patrick Forterre

Thermostable DNA polymerase/primase of the archaeal plasmid pTN2 from thermococcus nautilus 30/1


M Saleh

Paparazzi: a tool for in silico reconstruction of rapidly evolving viral genomes from small RNAs




Antibodies / Hybridomas


IP Ref.


DI 2012-32

High-affinity monoclonal anti-strep-tag-antibody C23.21

DI 2007-29

Murine monoclonal antibodies against the murine NEMO protein

DI 2006-40

Monoclonal antibodies recognizing the KERP1 protein of Entamoeba histolytica: basis of a diagnostic test for amoebiasis

DI 2003-97

F8-3 monoclonal antibody putatively directed against the SlyD protein of E. coli

DI 2003-96

Monoclonal antibodies against the Vga(A) protein involved in resistance to streptogramin A in staphylococcus strains

DI 2003-64

Monoclonal anti-GPIV antibodies

DI 2003-38

Antibodies, anti-hormones, anti-neuropeptides and cell anti-mediators for immunoanalysis or other in vitro uses

DI 2002-118

Monoclonal antibody against the C-terminal end of the T. cruzi ribosomal P2 protein: diagnostic applications in heart diseases and Chagas' disease

DI 2002-98

Monoclonal antibodies against the Bacillus anthracis exosporium used for spore detection and potential therapeutic and/or vaccine applications

DI 2002-46

Anti-MSP3 recombinant antibodies

DI 2002-44

Monoclonal antibodies against calreticulin. Diagnostic and intracellular targeting applications

DI 2002-33

Monoclonal antibodies against Bacillus anthracis PA and LF protein sequences. Diagnostic and therapeutic applications. Determination of protein sequences involved in protection.

DI 2001-51

Specific monoclonal antibody of the HBV pre-S1 region (ay subtype)

DI 2000-73

Anti-HCV monoclonal antibodies

DI 2000-10

H11-6 and H11-30 hybridomas producing anti-HLA-H antibodies for the diagnosis of human hemochromatosis

DI 1998-53

Anti-In1B and LRR sequence of Listeria hybridoma


Anti-In1A of Listeria hybridoma

DI 1998-40

Hybridoma of anti-IL1 receptor antagonist

DI 1998-17

Anti-SDF1 hybridoma

DI 1997-16

Ly49 A JR9-318 hybridoma

DI 1996-74

PV and PM rabies anti-virus hybridoma

DI 1994-62

Anti-interleukin 1 alpha hybridomas

DI 1994-37

Recombinant anti-rhesus D monoclonal antibodies (baculovirus-insect cell expression system)

DI 1994-04

Anti NDPK-A hybridoma, clone 37-6

DI 1991-37

Anti-blood group hybridoma, clone AC12

DI 1991-31

Anti-blood group B hybridoma, clone B2 A22

DI 1984-25

LAV hybridomas






Animal models


Invention Disclosure




F Arenzana

Transgenic mouse expressing a Cxcl12 gene (recombination/knock-in) selectively invalidated in sequences that abolish the interaction of its products alpha, beta, gamma with heparan sulfates of proteoglycans without affecting their agonist activity on the CXCR4 receptor


P. Bruhns

Human FcyRI(CD64)-expressing mice for inflammation and anaphylaxis modeling and anti-human FcyRI blocking mAbs for the prevention of disease


F. Lemonnier

Mutant mice humanized for HLA and related lines (Triple Knock-Out / Kb-/-, Db-/-, Beta2M-/-)

* See supplementary table below


H Strick-Marchand/ J Di Santo

A novel model for hepatotropic diseases: mice harboring a humanized immune system and liver (HIS-HUHEP mice)


S. Garcia

Optimization of immunodeficient RAG yc mB2m I-AB HLA-A2 HLA-DRI C5 mice by the expression of human SIRPa in murine macrophages


S. Garcia

Use of immunodeficient host mice lacking murine CMH molecules and expressing HLA molecules for human precursor xenotransplantation


* tableau annexe




HHD  (HLA-A02.01)

â2m-/-, H-2Db-/-

HHD/DR1  (HLA-A02.01, DR1)

â2m-/-, H-2Db-/-, IAâb-/-, IAáb-/-, IEâb-/-


 H-2Kb-/-, H-2Db-/-

HLA-A24.02 (monochain as for HHD mice)

â2m-/-, H-2Kb-/-, H-2Db-/-

HLA-A01.03 (monochain as for HHD mice)

â2m-/-, H-2Kb-/-, H-2Db-/-

HLA-B8.01 (monochain as for HHD mice)

â2m-/-, H-2Kb-/-, H-2Db-/-

HLA-B27.05 (monochain as for HHD mice)

â2m-/-, H-2Kb-/-, H-2Db-/-

HLA-B35.01 (monochain as for HHD mice)

â2m-/-, H-2Kb-/-, H-2Db-/-

HLA-B44.02 (monochain as for HHD mice)

â2m-/-, H-2Kb-/-, H-2Db-/-

HLA-Cw7.01 (monochain as for HHD mice)

â2m-/-, H-2Kb-/-, H-2Db-/-



Cell lines


Invention Disclosure




U Maskos

In vitro model of human preneoplastic bronchial lesions: a new screening system


N Naffakh

Generation of mammalian cell lines that constitutively express GFP1-10 and complementation with GFP-S11-TAGGED PB2 of recombinant influenza viruses following infection, allowing the monitoring of PB2 accumulation and the imaging of PB2 localization and dynamics in live cells during an infection


Charneau, Lavigne, Jacob

Development of a cell line that allow to measure the interaction between HIV-1 integrase and the LEDGF/p75 cellular protein. Cell line used to identify and to test molecules inhibiting HIV-1 replication


P Bruhns

Bioluminescent HER2(Erb-B2)+ human breast cancer cell line for monitoring antibody immunotherapy


P Bruhns


Library of membrane-expressed human and mouse antibody receptors


F Traincard

Wild type and Nemo-/- mouse embryonic fibroblasts (MEF) and wild type human T lymphocytes (Jurkat E6.1) cells carrying an NF-kappaB promoter dependent luciferase reporter gene


JC Manuguerra


In vitro cultures of mosquito cells competent for hepatitis C virus maintenance and production




Bacterial strains

The Collection of Institut Pasteur (CIP) website


The CIP is the Institut Pasteur's largest certified collection in terms of volume.


Invention Disclosure




D Leduc

Bioluminescent Helicobacter pylori strains with luxA-luxB or luxa-luxB-luxC-luxD-luxE genes on their chromosomes


C Buchrieser

Development of a clear gelose medium for Legionella pneumophila growth



Other Materials


Invention Disclosure




N Naffakh/Y Jacob

Replication-competent recombinant influenza viruses expressing a polymerase subunit fused to a domain of "Gaussia princeps luciferase"


Software/Computational biology


Invention Disclosure




Jb Masson

Research in random environments without perception of the environment 


C D’Enfert

Barcode Toolbox


A Blondel

Framework approach to calculate plausible low energy and connected intermediate states in complex conformational transitions and its application to improve virtual screening of active compounds by conception of structural targeting strategies


Updated on 20/02/2014


Contact & address

Business Development

Technology Transfer & Entrepreneurship Office

Email : businessdevelopment@pasteur.fr 

Institut Pasteur

28 rue du Docteur Roux

75724 Paris Cedex 15 – France